Publikasi Scopus FKUI 2021 per tanggal 31 Agustus 2021 (582 artikel)

Sun X., Li R., Cai Y., Al-Herz A., Lahiri M., Choudhury M.R., Hidayat R., Suryana B.P.P., Kaneko Y., Fujio K., Van Hung N., Pandya S., Pang L.K., Katchamart W., Sigdel K.R., Paudyal B., Narongroeknawin P., Chevaisrakul P., Sun F., Lu Y., Ho C., Yeap S.S., Li Z., on behalf of APLAR RA SIG group
57211390694;57026629100;56599490900;6508020635;26039213500;55408508400;37067327300;15728721800;57226139851;57226092310;57226144210;7103287746;57226150004;26654177400;56123182100;9244632800;35099091000;57191876780;57226138715;57226146642;57226138308;6701698220;57214875227;
Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region
2021
The Lancet Regional Health - Western Pacific
15
100240
Department of Rheumatology & Immunology, Peking University People's Hospital, 11 Xizhimen South St.Beijing 100044, China; Department of Rheumatology & Immunology, Peking University Shenzhen Hospital, Shenzhen, China; Rheumatology Unit, Department of Internal Medicine, Al-Amiri Hospital, Kuwait City, Kuwait; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Rheumatology, Bangabandhu Sheikh Mujib Medical UniversityDhaka, Bangladesh; Department of Internal Medicine, Cipto Mangunkusumo National Hospital Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rheumatology Division, Internal Medicine Department, Brawijaya University - Saiful Anwar Hospital, Indonesia; Division of Rheumatology, Department of Internal Medicine, Keio University School of MedicineTokyo, Japan; Department of Allergy and Rheumatology, Graduate School of Medicine, The University of TokyoTokyo, Japan; Department of Rheumatology, Bach Mai Hospital, Giai Phong Road, Dong Da DistrictHanoi, Viet Nam; Vedanta institute of medical sciences and VS hospital, Ahmedabad, India; Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore; Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Department of Internal Medicine, Patan Academy of Health Sciences, Kathmandu, Nepal; Division of Rheumatology, Department of Medicine, Phramongkutklao Hospital and College of MedicineBangkok, Thailand; Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityBangkok, Thailand; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian DistrictBeijing 100191, China; School of Mathematical Science, Nankai University, No. 94 Weijin Road, Nankai DistrictTianjin 300071, China; Division of Rheumatology, Dept of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong; Department of Medicine, Subang Jaya Medical Centre, Selangor, Malaysia
Sun, X., Department of Rheumatology & Immunology, Peking University People's Hospital, 11 Xizhimen South St.Beijing 100044, China; Li, R., Department of Rheumatology & Immunology, Peking University People's Hospital, 11 Xizhimen South St.Beijing 100044, China; Cai, Y., Department of Rheumatology & Immunology, Peking University Shenzhen Hospital, Shenzhen, China; Al-Herz, A., Rheumatology Unit, Department of Internal Medicine, Al-Amiri Hospital, Kuwait City, Kuwait; Lahiri, M., Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Choudhury, M.R., Department of Rheumatology, Bangabandhu Sheikh Mujib Medical UniversityDhaka, Bangladesh; Hidayat, R., Department of Internal Medicine, Cipto Mangunkusumo National Hospital Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Suryana, B.P.P., Rheumatology Division, Internal Medicine Department, Brawijaya University - Saiful Anwar Hospital, Indonesia; Kaneko, Y., Division of Rheumatology, Department of Internal Medicine, Keio University School of MedicineTokyo, Japan; Fujio, K., Department of Allergy and Rheumatology, Graduate School of Medicine, The University of TokyoTokyo, Japan; Van Hung, N., Department of Rheumatology, Bach Mai Hospital, Giai Phong Road, Dong Da DistrictHanoi, Viet Nam; Pandya, S., Vedanta institute of medical sciences and VS hospital, Ahmedabad, India; Pang, L.K., Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore; Katchamart, W., Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Sigdel, K.R., Department of Internal Medicine, Patan Academy of Health Sciences, Kathmandu, Nepal; Paudyal, B., Department of Internal Medicine, Patan Academy of Health Sciences, Kathmandu, Nepal; Narongroeknawin, P., Division of Rheumatology, Department of Medicine, Phramongkutklao Hospital and College of MedicineBangkok, Thailand; Chevaisrakul, P., Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityBangkok, Thailand; Sun, F., Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian DistrictBeijing 100191, China; Lu, Y., School of Mathematical Science, Nankai University, No. 94 Weijin Road, Nankai DistrictTianjin 300071, China; Ho, C., Division of Rheumatology, Dept of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong; Yeap, S.S., Department of Medicine, Subang Jaya Medical Centre, Selangor, Malaysia; Li, Z., Department of Rheumatology & Immunology, Peking University People's Hospital, 11 Xizhimen South St.Beijing 100044, China; on behalf of APLAR RA SIG group
Background: Clinical remission is an attainable goal for Rheumatoid Arthritis (RA). However, data on RA remission rates from multinational studies in the Asia-Pacific region are limited. We conducted a cross-sectional multicentric study to evaluate the clinical remission status and the related factors in RA patients in the Asia-Pacific region. Methods: RA patients receiving standard care were enrolled consecutively from 17 sites in 11 countries from APLAR RA SIG group. Data were collected on-site by rheumatologists with a standardized case-report form. Remission was analyzed by different definitions including disease activity score using 28 joints (DAS28) based on ESR and CRP, clinical disease activity index (CDAI), simplified disease activity index (SDAI), Boolean remission definition, and clinical deep remission (CliDR). Logistic regression was used to determine related factors of remission. Findings: A total of 2010 RA patients was included in the study, the overall remission rates were 62•3% (DAS28-CRP), 35•5% (DAS28-ESR), 30•8% (CDAI), 26•5% (SDAI), 24•7% (Boolean), and 17•1% (CliDR), respectively, and varied from countries to countries in the Asia-Pacific region. Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) prescription rate was low (17•9%). Compared to patients in non-remission, patients in remission had higher rates of b/tsDMARDs usage and lower rates of GC usage. The favorable related factors were male sex, younger age, fewer comorbidities, fewer extra-articular manifestations (EAM), and use of b/tsDMARDs, while treatment with GC was negatively related to remission. Interpretation: Remission rates were low and varied in the Asia-Pacific region. Treatment with b/tsDMARDs and less GC usage were related to higher remission rate. There is an unmet need for RA remission in the Asia-Pacific region. © 2021
Elsevier Ltd
26666065
Article
#N/A
#N/A
#N/A